IP Library Granted Patent US 7,790,175
Granted Patent B2
US 7,790,175 · App. 11/996,961 · Granted Sep 7, 2010

Strain of turkey tail mushroom, extract from the same, and use of the same

Assignee: Nikken Sohonsha Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,790,175
App. No.
11/996,961
Granted
Sep 7, 2010
Kind
B2
Abstract

The present invention provides a new strain of turkey tail mushroom ( Trametes versicolor (L.: Fr.) Pilat) having excellent biological activities (Accession number: FERM BP-10633). The strain is excellent in platelet aggregation inhibitory effect, chemokine gene expression inhibitory effect, antimutagenic effect, antitumor effect, antihypertensive effect, and immunomodulatory effect. The effect of the strain is enhanced synergistically by combining with microalgae and other basidiomycetes. The turkey tail mushroom of the present invention has high safety, and a possibility that a side effect is caused because of long-term continuous use is very low. Thus, it is useful for food/drink, cosmetics, pharmaceuticals or the like, the objective of which is the prevention and improvement in inflammation, allergy, tumor, and other diseases. The turkey tail mushroom strain of the present invention has very high hyphal growth property and very high physiological functions compared with conventional strains; therefore, it can be used stably.

Claims (18)

1. An isolated culture of a strain of turkey tail mushroom ( Trametes versicolor (L.:Fr.)Pilat), wherein the accession number of the strain is FERM BP-10633.

2. A platelet aggregation inhibitor comprising, as an active component, the turkey tail mushroom culture according to claim 1 and/or its extract.

3. A chemokine gene expression inhibitor comprising, as an active component, the turkey tail mushroom culture according to claim 1 and/or its extract.

4. An antimutagenic agent comprising, as an active component, the turkey tail mushroom culture according to claim 1 and/or its extract.

5. An antitumor agent comprising, as an active component, the turkey tail mushroom culture according to claim 1 and/or its extract.

6. An antihypertensive agent comprising, as an active component, the turkey tail mushroom culture according to claim 1 and/or its extract.

7. An immunomodulatory agent comprising, as an active component, the turkey tail mushroom culture according to claim 1 and/or its extract.

8. A composition for oral use comprising the turkey tail mushroom culture according to claim 1 and/or its extract.

9. The composition for oral use according to claim 8 , further comprising one or more selected from the group consisting of microalgae, other basidiomycetes, and extracts thereof.

10. The composition for oral use according to claim 8 , wherein the composition is a food or a drink.

11. The composition for oral use according to claim 8 , wherein the composition is a pharmaceutical composition.

12. A skin external composition comprising the turkey tail mushroom culture according to claim 1 and/or its extract.

13. The skin external composition according to claim 12 , further comprising one or more selected from the group consisting of microalgae, other basidiomycetes, and extracts thereof.

14. A method of treating a tumor, which comprises administering an effective amount of the turkey tail mushroom culture according to claim 1 and/or its extract to a mammal with the tumor.

15. A method of treating hypertension, which comprises administering an effective amount of the turkey tail mushroom culture according to claim 1 and/or its extract to a mammal.

16. A method of maintaining or stimulating immunity, which comprises administering an effective amount of the turkey tail mushroom culture according to claim 1 and/or its extract to a mammal.

17. The composition for oral use according to claim 9 , wherein the composition is a food or a drink.

18. The composition for oral use according to claim 9 , wherein the composition is a pharmaceutical composition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 2, 2008
From: EGUCHI, FUMIO; SUMI, RYO; MORI, NOBUO
To: NIKKEN SOHONSHA CORPORATION
Reel/Frame 020742/0102 →
Priority Claims (1)
JP 2005-218554 · Jul 28, 2005 · national
Continuity (1)
Related Publication 20100047269A1 · Feb 25, 2010